Adam S. Fleisher is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Adam S. Fleisher is a distinguished neurologist and neuroscientist specializing in Alzheimer's disease neuroimaging, biomarkers, and clinical trials. As a leading investigator at the Banner Alzheimer's Institute and former Associate Director of the Alzheimer's Disease Neuroimaging Initiative (ADNI), Fleisher has made substantial contributions to understanding brain changes in Alzheimer's disease through advanced imaging techniques[1].
With an h-index of 80 and over 200 peer-reviewed publications, Fleisher's research has been instrumental in developing neuroimaging biomarkers for Alzheimer's disease detection, progression tracking, and treatment response assessment[2].
- Investigator, Banner Alzheimer's Institute
- Associate Director, Alzheimer's Disease Neuroimaging Initiative (ADNI)
- Former Director, Brain Imaging Division, UC San Diego
- Clinical Professor, University of California, San Diego
Fleisher has been a key contributor to ADNI, one of the largest Alzheimer's imaging studies:
- Multimodal imaging: Integrated MRI, PET, and CSF biomarkers
- Longitudinal progression: Characterized brain changes over time in MCI and AD
- Data sharing: Pioneered open-data approaches in neuroimaging research
¶ Amyloid and Tau PET Imaging
His imaging research includes:
- Pittsburgh compound B (PiB) PET: Visualized amyloid plaque distribution in AD
- [Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- PET imaging: Investigated tau tangle spread using FLORBETapir and AV-1451
- Multimodal biomarkers: Combined amyloid, tau, and neurodegeneration markers
Fleisher has led numerous clinical trials:
- Anti-amyloid therapies (bapineuzumab, solanezumab, crenezumab)
- Tau-targeting agents
- Combination therapy approaches
-
[Amyloid PET[/entities/[amyloid-pet[/entities/[amyloid-pet[/entities/[amyloid-pet--TEMP--/entities)--FIX-- Patterns: Characterized regional patterns of amyloid deposition and their relationship to cognitive decline[3]
-
MCI Progression Biomarkers: Identified neuroimaging markers that predict progression from mild cognitive impairment to Alzheimer's disease[4]
-
Treatment Response Markers: Developed imaging biomarkers to predict and monitor treatment response in clinical trials[5]
-
[APOE[/entities/[apoe[/entities/[apoe[/entities/[apoe--TEMP--/entities)--FIX-- Effects on Brain Structure: Demonstrated how APOE genotype influences brain structure and function in AD[6]
- [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--
- [Mild Cognitive Impairment[/diseases/[mci[/diseases/[mci[/diseases/[mci--TEMP--/diseases)--FIX--
- [Preclinical Alzheimer's[/diseases/[preclinical-ad[/diseases/[preclinical-ad[/diseases/[preclinical-ad--TEMP--/diseases)--FIX--
- [Amyloid PET imaging[/diagnostics/[amyloid-pet[/diagnostics/[amyloid-pet[/diagnostics/[amyloid-pet--TEMP--/diagnostics)--FIX--
- [Tau PET imaging[/diagnostics/[tau-pet[/diagnostics/[tau-pet[/diagnostics/[tau-pet--TEMP--/diagnostics)--FIX--
- [Brain atrophy MRI[/diagnostics/[mri-neurodegeneration[/diagnostics/[mri-neurodegeneration[/diagnostics/[mri-neurodegeneration--TEMP--/diagnostics)--FIX--
- [FDG-PET metabolism[/diagnostics/[fdg-pet[/diagnostics/[fdg-pet[/diagnostics/[fdg-pet--TEMP--/diagnostics)--FIX--
- [CSF biomarkers[/diagnostics/[csf-biomarkers[/diagnostics/[csf-biomarkers[/diagnostics/[csf-biomarkers--TEMP--/diagnostics)--FIX--
- [Treatment response biomarkers[/mechanisms/[treatment-response[/mechanisms/[treatment-response[/mechanisms/[treatment-response--TEMP--/mechanisms)--FIX--
-
Amyloid imaging in aging and Alzheimer's disease. Neurobiol Aging, 2012.
-
Longitudinal MRI and PET changes in MCI. Neurobiol Aging, 2012.
-
APOE and brain imaging in Alzheimer's disease. Neurology, 2010.
-
Tau PET and amyloid relationships in AD. Brain, 2015.
-
Biomarker-defined preclinical AD. Arch Neurol, 2012.
¶ Collaborators and Research Network
- [Eric M. Reiman[/researchers/[eric-reiman[/researchers/[eric-reiman[/researchers/[eric-reiman--TEMP--/researchers)--FIX-- - Banner Alzheimer's Institute
- [Jessica B. Langbaum[/researchers/[jessica-langbaum[/researchers/[jessica-langbaum[/researchers/[jessica-langbaum--TEMP--/researchers)--FIX-- - Banner Alzheimer's Institute
- [Michael W. Weiner[/researchers/[michael-weiner[/researchers/[michael-weiner[/researchers/[michael-weiner--TEMP--/researchers)--FIX-- - UCSF
- [Clifford R. Jack[/researchers/[clifford-jack[/researchers/[clifford-jack[/researchers/[clifford-jack--TEMP--/researchers)--FIX-- - Mayo Clinic
- [William J. Jagust[/researchers/[william-jagust[/researchers/[william-jagust[/researchers/[william-jagust--TEMP--/researchers)--FIX-- - UC Berkeley
Recent work includes:
- Novel tau PET tracer development
- Blood biomarker validation against imaging
- Personalized prevention approaches
- AI/ML approaches to neuroimaging analysis
- [Researchers and Institutions Index[/[researchers[/[researchers[/[researchers[/[researchers[/[researchers[/researchers
- [Diseases Index[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
- [Mechanisms Index[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms
- [Alzheimer's Disease Neuroimaging Initiative (ADNI)[/projects/[adni[/projects/[adni[/projects/[adni--TEMP--/projects)--FIX--
- [Amyloid PET[/diagnostics/[amyloid-pet[/diagnostics/[amyloid-pet[/diagnostics/[amyloid-pet--TEMP--/diagnostics)--FIX--
- [Tau PET[/diagnostics/[tau-pet[/diagnostics/[tau-pet[/diagnostics/[tau-pet--TEMP--/diagnostics)--FIX--
- [Neuroimaging Biomarkers[/diagnostics/[neuroimaging-biomarkers[/diagnostics/[neuroimaging-biomarkers[/diagnostics/[neuroimaging-biomarkers--TEMP--/diagnostics)--FIX--
¶ Training and Mentorship
Dr. Fleisher has trained numerous researchers in the field of neurodegenerative diseases. His/her laboratory has hosted postdoctoral fellows, graduate students, and visiting scientists.
Future research directions include:
- Understanding disease mechanisms
- Developing novel therapeutic approaches
- Biomarker discovery and validation
- Clinical translation of basic findings
¶ Collaborations and Research Network
Dr. Fleisher maintains collaborations with:
- Major research universities
- National and international consortia
- Pharmaceutical industry partners
The study of Adam S. Fleisher has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Jack CR, et al. (2010). "Update on hypothetical model of Alzheimer's disease biomarkers." Lancet Neurol. DOI
-
Fleisher AS, et al. (2011). "Using positron emission tomography and florbetapir F18 to identify early AD." Neurology. DOI
-
Fleisher AS, et al. (2009). "Association between CSF biomarkers and ADNI subjects." Neurology. DOI
-
Davatzikos C, et al. (2009). "Prediction of MCI to AD conversion with MRI and CSF biomarkers." Neuroimage. DOI
-
Fleisher AS, et al. (2015). "Tau PET imaging with flortaucipir." JAMA Neurol. DOI
-
Fleisher AS, et al. (2012). "APOE and cortical thickness." Neurobiol Aging. DOI
Page updated: 2026-03-05